PIKTOR — Topline data
Late 2026
PIKTOR is currently being evaluated in an ongoing Phase 2 trial in second-line advanced endometrial cancer (Study FTH-PIK-201), with topline data anticipated by year-end 2026.Source filing
FTH biotech catalysts & pipeline
FAETH THERAPEUTICS INC · Data as of 2026-09-08
Upcoming catalysts
PIKTOR — Full data
2027
We intend to establish PIKTOR's initial therapeutic proof of concept in endometrial cancer through our ongoing Phase 2 trial (FTH-PIK-201), with topline data anticipated by year-end 2026 and longer-term follow-up data in 2027.Source filing
PIKTOR — Full data
2028
Concurrently, we plan to broaden PIKTOR's development into advanced HR+/HER2- breast cancer through Study FTH-PIK-101, for which we announced in May 2026 that the first patient was dosed, and expect interim dose escalation data and expansion cohort initiation in 2027, and expansion cohort data in 2028.Source filing